FDA Approved: TAKHZYRO — Original Application (Takeda Pharmaceuticals America, Inc.)

View source ↗

Summary

FDA approved TAKHZYRO (lanadelumab-flyo) from its original application for the prevention of attacks in patients with hereditary angioedema.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• Takhzyro (lanadelumab)

Snippet

ORIG AP for TAKHZYRO (LANADELUMAB-FLYO)